Xu-yuan Li

Suggest Changes
Learn More
To compare the addition of targeted agents to fulvestrant with fulvestrant alone in hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy; a meta-analysis of all(More)
  • 1